MAPT and Alzheimer disease: Hence, plasma biomarkers for AD are either directly (Aβ42/40) or indirectly (e.g., tau phosphorylation, astrocyte reactivity and neurodegeneration) associated with presence of Aβ pathology and could be used to indicate elevated Aβ burden for therapeutic trials.